Evidence map›Paper›PMID 35936000›Full record

ArticleFrontiers in immunology2022

Characterization of the immune cell infiltration landscape in myxofibrosarcoma to aid immunotherapy.

Zi-Yue Zhao, Zhuo-Yuan Chen, Bin Yu, Bo Xiao, Li-Yan Liu, Yu Xia, Ao-Yu Li, Ping-Xiao Wang, Cheng Xiang, Chao Liu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zi-Yue ZhaoDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Zhuo-Yuan ChenDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Bin YuDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Bo XiaoDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Li-Yan LiuDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Yu XiaDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Ao-Yu LiDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Ping-Xiao WangDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Cheng XiangDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Chao LiuDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Hui-Qin YangDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Hui LiDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.
Tao XiaoDepartment of Orthopedics, Second Xiangya Hospital, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myxofibrosarcoma (MFS) is a highly malignant subtype of soft tissue sarcoma, accounting for 5% of cases. Immunotherapy guided by immune cell infiltration (ICI) is reportedly a promising treatment strategy. Here, MFS samples (n = 104) from two independent databases were classified as ICI clusters A/B/C and gene clusters A/B/C. Then, a close relationship between ICI and gene clusters was established. We found that the features of these clusters were consistent with the characteristics of immune-inflamed tumors (cluster C), immune-desert tumors (cluster B), and immune-excluded tumors (cluster A). Moreover, cluster C was sensitive to immunotherapy. Finally, an independent ICI score was established to predict the therapeutic effect, which has prospects for application in guiding immunotherapy during clinical practice.

Indexed as

FibrosarcomaTumor MicroenvironmentBiomarkers, TumorHumansImmunotherapyPrognosisBiomarkers, TumorICIimmunotherapyMFSprognosisTME

Identifiers

PMID35936000
PMCPMC9353264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.